Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01494103 | Administration of Donor T Cells With the Caspase-9 Suicide Gene(DOTTI) | active not recruiting | Phase 1 | 15 | Baylor College of MedicineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04836507 | Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients | recruiting | Phase 1 / Phase 2 | 91 | Curocell Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06996119 | Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07677878 | Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL | recruiting | Phase 1 | 60 | Liping DouOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678307 | A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07679919 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies | not yet recruiting | Phase 1 | 27 | Luminary TherapeuticsINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03241940 | Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies | active not recruiting | Phase 1 | 33 | Stanford UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06357182 | Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 1 | 30 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03571321 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 15 | University of ChicagoOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03805932 | Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT01815749 | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07575971 | Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 30 | Liping DouOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668557 | Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia(ICG415-AML-01) | recruiting | Phase 1 | 18 | iCell Gene TherapeuticsINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT02553460 | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | active not recruiting | Phase 1 / Phase 2 | 50 | St. Jude Children's Research HospitalOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT03709758 | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML | active not recruiting | Phase 1 | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06551584 | Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT | recruiting | Phase 1 | 24 | Stanford UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03128034 | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia | recruiting | Phase 1 / Phase 2 | 75 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03277729 | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | active not recruiting | Phase 1 / Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03670966 | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04581512 | Study to Evaluate the Safety and Tolerability of EP0042 | recruiting | Phase 1 / Phase 2 | 70 | Ellipses PharmaINDUSTRY | 3 | Jun 22, 2026 | clinicaltrials |
| NCT05549661 | Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms | recruiting | Phase 1 | 25 | Mayo ClinicOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05756777 | A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06017258 | A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia | recruiting | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07356154 | A Study of Revumenib and Mezigdomide in People With Leukemia | recruiting | Phase 1 / Phase 2 | 52 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03113643 | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | recruiting | Phase 1 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04024761 | A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation | recruiting | Phase 1 | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05475925 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | recruiting | Phase 1 / Phase 2 | 200 | Dren BioINDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT06138587 | Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation | recruiting | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07011004 | A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03690011 | Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells | active not recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651878 | Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment | recruiting | Phase 1 | 24 | MendusINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02074839 | Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | recruiting | Phase 1 | 291 | Institut de Recherches Internationales ServierOTHER | 2 | Jun 15, 2026 | clinicaltrials |
| NCT02427451 | Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 87 | Kerry RogersOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05768932 | BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 260 | SillaJen, Inc.INDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT07575919 | Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL | recruiting | Phase 1 / Phase 2 | 20 | Liping DouOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT01430390 | In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies | active not recruiting | Phase 1 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03162536 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | active not recruiting | Phase 1 / Phase 2 | 190 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03602157 | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | active not recruiting | Phase 1 | 43 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04047641 | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05834244 | A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) | recruiting | Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06448013 | A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia | recruiting | Phase 1 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03041688 | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03622788 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03983824 | Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04190550 | Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03016377 | Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | active not recruiting | Phase 1 | 15 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03247088 | Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 74 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04892277 | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies | recruiting | Phase 1 | 25 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 1, 2026source: clinicaltrials